Palatin Technologies, Inc. (0KF3) Earnings Call Transcript & Summary
February 15, 2022
Earnings Call Speaker Segments
Operator
operatorGood day, everyone, and welcome to the conference call on Palatin's operating results for the second quarter of fiscal year 2022. Please note that this call is being recorded. Before we get into our remarks, I want to point out that anything Palatin states that isn't a historical fact could constitute a forward-looking statement. Such statements rest on assumptions that might not turn out to be accurate, and actual results could differ materially from what is anticipated because of the various risks and uncertainties covered in the company's latest filings with the Securities and Exchange Commission. When you evaluate these forward-looking statements regarding Palatin's prospects, please weigh those risks and uncertainties carefully. At this point, I'll hand today's call to our host, Dr. Carl Spana, Palatin's President and Chief Executive Officer. Please go ahead.
Carl Spana
executiveThanks. Morning, everyone, and thanks for joining us for the Palatin Technologies call covering the second quarter of fiscal 2022. This is Dr. Carl Spana speaking — I serve as CEO and President of Palatin. Joining me today is Steve Wills, our Executive Vice President, Chief Financial Officer and Chief Operating Officer at Palatin. Steve?
Stephen Wills
executiveThank you, Carl. Good morning, and good afternoon to everyone. Turning to Palatin's financial results for the second fiscal quarter, which closed on December 31, 2021, here is how things look. Total revenue is made up of gross product sales of Vyleesi, net of allowances and accruals, along with revenue from licensing contracts. As a reminder, Vyleesi is the commercial product we offer for treating premenopausal women who have hypoactive sexual desire disorder. For the quarter that ended December 31, 2021, gross product sales of Vyleesi to pharmacy distributors came to roughly $800,000, and net product revenue was approximately $72,000. That compares with gross product sales of about $900,000 and negative net product revenue of approximately $164,000 in the same quarter of 2020. Now, on Vyleesi specifically: during the quarter ending December 31, 2021, gross product sales fell 18% while net product revenue rose 144% versus the comparable quarter in 2020. Measured against the prior quarter, which ended September 30, 2021, gross product sales dropped 46% and net product revenue dropped 55%. Importantly, this decline came mainly because pharmacy distributors were minimizing their inventory levels at year-end. Total prescriptions dispensed stayed flat relative to the same period in 2020 and to the prior quarter ending September 30, 2021. Commercial insurance reimbursement, as well as net revenue per prescription dispensed, rose significantly compared with the comparable quarter in 2020 and with the prior quarter that ended September 30, 2021.
Stephen Wills
executiveAdditionally, during the quarter that closed on December 31, 2021, Palatin recorded $250,000 of license and contract revenue under the license agreement it has with Fosun Pharma. In the comparable quarter of 2020, no licensed revenues were recognized. Turning to operating expenses: total operating expenses for the quarter ending December 31, 2021, came to $8.8 million, versus $9.1 million in the same quarter of 2020. That decline in operating expenses resulted from lower commercial expenses tied to Vyleesi, which was offset by higher research and development expenses, mainly stemming from moving PL9643 forward into a pivotal Phase 3 clinical trial for patients with dry eye disease. On cash flows, Palatin's net cash used in operations during the quarter ended December 31, 2021, was $6.3 million, compared with net cash used in operations of $14.4 million in the same period of 2020. The reduction largely reflects a one-time negotiated payment of roughly $7 million made in the quarter ended December 31, 2020. That payment was tied to inventory purchase commitments for Vyleesi that Palatin took on under our termination agreement with AMAG Pharmaceuticals, though it also encompassed $16.3 million in payments made by AMAG to Palatin. As for net loss, Palatin posted a net loss of $8.7 million, or $0.04 per basic and diluted common share, for the quarter ended December 31, 2021, compared with a net loss of $10 million, or approximately $0.04 per basic and diluted common share, in the same period of 2020.
Stephen Wills
executiveOn the cash front, as of December 31, 2021, Palatin had $47.3 million in cash and cash equivalents, along with roughly $600,000 in accounts receivable. That compares with $53.4 million in cash and cash equivalents and $900,000 in accounts receivable as of September 30, 2021. Under our present operating plan, Palatin expects that the cash and cash equivalents we already hold will be enough to cover currently anticipated operating expenses through at least March 31, 2023. At this point, I'll hand the call back over to Carl.
Carl Spana
executiveThanks, Steve. Now on Vyleesi: our operational goal has been to fine-tune the key metrics underpinning the commercial worth of Vyleesi — in other words, how we generate revenue from a prescription. During the quarter, commercial insurance coverage, net revenue per prescription and prescription refill rates each rose versus earlier quarters. Our end goal is to relicense Vyleesi to a dedicated partner, securing continued availability of Vyleesi as a treatment option for premenopausal women with hypoactive sexual desire disorder and delivering a return on our investment. We remain in discussions with prospective partners in the U.S. and other territories, and when a potential license happens depends on our agreeing on several terms with the right partner. Next, throughout a wide range of inflammatory and autoimmune diseases, a vital medical need persists for new treatments that give patients and clinicians safe and effective options. Our R&D operations concentrate on developing drugs that modulate the melanocortin system — a new treatment modality for patients suffering from pathological inflammation — with a primary focus on ophthalmic diseases such as diabetic retinopathy, dry eye and uveitis. A lot of today's treatments for inflammatory autoimmune diseases act by blocking one or more pro-inflammatory pathways, which can lead to immune suppression and major safety concerns.
Carl Spana
executiveThe way we do this is by going after the melanocortin system — one of the body's built-in ways of calming inflammation — which restores the immune system to a normal state and helps tissue heal. Our belief is that this lets us create highly differentiated therapeutics that combine efficacy with a superior safety profile. We have a plan with multiple layers for deepening our molecular-level understanding of the melanocortin system and for establishing clinical validation of melanocortin-based therapeutics. Our clinical development programs, which include ocular and non-ocular indications, are built to show the broad utility of the melanocortin system as a new target for drug development. If we succeed, we will have created a new class of therapeutics for treating inflammatory and autoimmune diseases. Our first product, happily delivered, is PL9643 — our most advanced melanocortin agonist for treating ocular diseases affecting the tissues of the interior or front segment of the eye. The first indication for PL9643 is dry eye disease; in December 2021, we began enrollment in a pivotal Phase 3 dry eye disease study called Melody 1. In Melody 1, the safety and efficacy of PL9643 versus vehicle control are being evaluated in patients with moderate to severe dry eye disease over a 12 week treatment period. The study is targeted to enroll 240 patients and includes an interim data assessment that an independent data monitoring committee will conduct, which will allow us to increase the number of subjects if needed, reducing the risk of an underpowered study.
Carl Spana
executiveThree co-primary endpoints and three key secondary endpoints are going to be made up of scientists hypnosis, dry disease. More will be determined from a detailed analysis of the Phase 2 data. Melody 1 is right now enrolling patients at multiple sites in the U.S., and the interim data assessment is scheduled for May 2022, with preliminary data in the second half of 2022. Following this success, Palatin will start the second Phase 3 PL9643 drive the study called Melody 2 and an open label safety study called Melody 3. The three melody PL9643 drives in these studies are going to provide the safety and efficacy data needed to file a new drug application with the FDA. The emerging profile of 9643, with its rapid therapeutic onset, excellent ocular tolerability and safety profile, is a potentially distinct advance in dry eye disease therapy. If the Phase 2 results get confirmed in the upcoming Phase 3 clinical study, we believe that PL-9643 has potential for substantial penetration into the multi-billion dollar dry eye disease market. With PL9643 and other melanocortin, there will be utility in treating multiple front of the eye disease indications, and we are planning to advance a second part of the eye disease indication to an investigational new drug filing in 2022 as well.
Carl Spana
executiveTurning now to the back of the eye. PL9654 is a melanocortin agonist being developed to treat multiple forms of retinopathy. Right now we're carrying out the pre-clinical work needed to submit an IND to the FDA, which would let us start clinical activities with PL9654. We recently shared pre-clinical data at the 2021 Annual Meeting of the American Society of Retinal Specialists describing the protective effects of PL9654 in models of retinopathy, and that presentation received a top 10 poster designation. The current market — the current drug market for the various retinopathy drugs came to roughly $20 billion in 2021 and is expected to exceed 27 billion by the end of 2025. A substantial need persists for innovative new retinal disease treatments, and we believe PL9654, though still early in development, holds tremendous potential to benefit patients with retinal disease and to capture a meaningful share of this extremely large market. Obviously, the eye — moving on to other parts of the body. For our PL8177 oral formulation for Ulcerative Colitis, we remain on schedule to begin patient enrollment and a Phase 2 proof-of-concept study in the second quarter of 2022. We expect initial data readout in the second half of 2022 as well.
Carl Spana
executiveThis marks our first clinical trial meant to assess whether a chosen melanocortin 1 receptor agonist could work as a therapy for inflammatory bowel diseases. The study is going to assess how safe oral PL8177 is and how well it works, along with a positive — and the results from it will contribute toward validating the melanocortin system as a target for innovative drugs, and will also matter for our business development and licensing efforts around oral PL8177. The market for drugs treating various inflammatory bowel diseases runs into the multi-billion dollar range, and a substantial need persists for new, safe and effective options that can expand and advance treatment for these patients. The emerging safety and FC profile of PL8177, should it be confirmed, would represent a potential major step forward in treating inflammatory bowel disease, especially among the pediatric population. More details on our programs are available on our website, www.palatin.com. As a company, we are well-positioned to push forward a new mechanism for treating inflammatory and autoimmune diseases founded on drugs that modulate the melanocortin system. This year is an exciting one for Palatin, with data readouts on two major clinical programs and two additional programs moving toward clinical studies. So, to summarize, before we move into Q&A: PL9643 is actively enrolling patients in a Phase 3 pivotal dry disease study called Melody 1, with the interim analysis on schedule for May 2022 and data by year end 2022.
Carl Spana
executiveFor treating Ulcerative Colitis, Oral PL8177 is still on track to start enrolling patients in the second quarter of 2022. There's also a Phase 2 proof-of-concept clinical study, with preliminary data expected before year end 2022 as well. Each of these innovative drugs could become a significant player in growing multi-billion dollar markets. Our pipeline of innovative new treatments keeps expanding: PL9654, a melanocortin agonist for treating retinopathy, is moving toward an IND filing in clinical studies, and a novel melanocortin agonist — our second front-of-the-eye treatment — is also advancing toward an investigational drug filing in 2022. Vyleesi commercial activities keep showing significant improvement in the core metrics of insurance reimbursement, revenue per prescription, and prescription refills. We're also actively engaged in relicense, at least to a committed partner. With the support of clinical development programs and business development activities, Palatin scientists and collaborators are presenting at major medical meetings, and we have been actively publishing our research. Our communication efforts are establishing Palatin as a company developing exciting new treatments for ocular diseases. Looking forward to 2022, Steve and I are excited by the tremendous opportunity we have to advance a portfolio of highly differentiated innovative drugs that will positively impact patients and build shareholder value.
Carl Spana
executiveWe appreciate you tuning in to our call and for your ongoing support. The line is now open for your questions.
Operator
operatorThanks. <<operator_script>>. Our first question comes from Joe Pantginis at H.C. Wainwright. Go ahead, please.
Joe Pantginis
analystMorning, everyone, and thanks for taking my question. I hope you don't mind a couple of things. First, on the pivotal DED study, could you give us a bit more detail about the interim and what sort of news flow the street should expect? Will it simply carry on as planned, or is there a chance the study gets upsized?
Carl Spana
executiveThis is really an assessment rather than an analysis of data. So what they'll actually be doing is examining the power calculations that form the foundation of the study, and they'll advise us on whether an upsize is needed or whether we remain as we are. And just to note, adding these elements is a meaningful innovation to help drive these studies, which do carry a certain degree of variability. This kind of approach genuinely lets us confirm that the study isn't underpowered, especially when it comes to the key secondary endpoints — we truly want to secure some of those key secondary endpoints, since they'll matter for our label.
Joe Pantginis
analystUnderstood, that helps. And let's stay on ocular for a moment, I suppose. I realize this is a pretty broad-strokes kind of question, and you may not want to go too deep into it right now, but what about other front-of-the-eye indications that could interest you, plus further indications within the ocular space, even with 9654 and past that?
Carl Spana
executiveOf course, 9654 targets the back of the eye, but with 9643 and additional compounds we haven’t disclosed yet, the number of front-of-the-eye indications is limited. I mean, beyond dry eye, the ones that interest us would include conditions such as glaucoma—for instance, a very large market where new treatments are desperately needed. There are also various disease types tied to corneal function, things surrounding, for example, cataract surgery and other surgical procedures that require improved healing, where I believe many important agonists can genuinely assist in promoting better tissue healing, and so forth. Beyond that, a few indications exist that we aren’t prepared to disclose yet, which we think preclinical data can help clarify as truly representing new front-of-the-eye indications. So we are examining this very thoroughly. And I think during the next year, we’ll see a great deal of information emerge there.
Joe Pantginis
analystNo, that's fair, thanks. For my final question, if I could just change topics here — clearly Vyleesi has a lengthy history with your company, and it's good to see that you're getting more reimbursement engagement with the commercial payers. So I suppose the broad question is, to whatever extent you can or want to talk about it, how would you characterize the tone of your discussions as they're ongoing right now — but even more specifically, depending on how those discussions turn out, are you potentially looking at other options for Vyleesi, whether, I don't know, I'll just take a few wild guesses here, a spin out company, or even retaining it for yourself to expand Women's Health again?
Stephen Wills
executiveHey Joe, this is Steve, and I’ll handle that question. So, not in any specific order. On that final point, as Carl said and as we’ve said before, our aim is to relicense Vyleesi to a company that simply is a better fit for it than we are. Looking ahead, our strategy is squarely the autoimmune anti-inflammatory space, the ocular focus, the dry eye disease trials, the Ulcerative Colitis work, and eventually some further ocular treatments that we’ll shed light on. We had to focus. What I mean is we set certain metrics that we believe demonstrate the brand’s value. I’m not sure I want to say “the right hands,” but in the hands of someone who can do it justice, who has the infrastructure, who has the resources, and frankly, whose strategic vision is to grow the female healthcare landscape — we’ve accomplished that. I won’t go into exactly where we began, but when the product came back to us, we had single-digit insurance reimbursement, and in fact we had negative — don’t start with negative net revenue — so gross-to-net coming down to net. So at present, more than 50% of every prescription dispensed is covered by insurance, and we have quite solid insurance coverage.
Stephen Wills
executiveAnd more importantly, once you secure that kind of insurance coverage, your gross to net is going to go up substantially. That's really where we've focused our efforts. We still have social media that we're actively using, but we're not going to be adding feet on the ground. We've got several sales people in place right now. But we're not looking to expand 10, 15, 20, 25 to sales — that's going to be for the new part. So specifically on the tenor, we believe the tenor is good, and it's positive, because we're demonstrating that if we do A, something B that is good will happen: increased insurance reimbursement, increased gross to net on the prescriptions dispensed. So then it's very, very, somewhat easy to extrapolate in the right hands — the hands being someone for whom this is their strategy and their objective going forward — they can even do a better job than we've done with the insurance reimbursement and the gross to net. And then layer that in with the infrastructure that they have, specifically whether it's feet on the ground or just a lot more wherewithal for the market access. We think the product can do very well. So to be clear, the objective is to license it, continue the path of showing progress in our primary targeted metrics.
Stephen Wills
executiveSo that's what we're doing, and we expect to secure a good home for Vyleesi at some point in calendar '22. On your point, Joe — and I don't want to spend too much of the response on this — but we're approved for premenopausal women in HSDD on the right hand, with Lifecycle Management exploring other treatment paradigms, whether that's postmenopausal or some other areas, possibly even with the male for the hard-to-treat man out there. There are other opportunities that could actually be quite exciting on the right hand. So hopefully that was responsive, Joe?
Joe Pantginis
analystIt absolutely was. Thank you so much, everyone. I appreciate it.
Operator
operatorOur next question comes from Michael Higgins at Ladenburg Thalmann. Go ahead, please.
Michael Higgins
analystThanks, operator, and good morning everyone. I appreciate the chance to ask a few questions. First, I'm looking forward to your KOL event on March 7, but that raises something: since you've told them before, how will this one differ from the earlier events? Thanks.
Carl Spana
executiveAbsolutely, Mike, absolutely. In fact, I believe that's the only one scheduled for today. So, as we mentioned, we do have a dry eye disease Key Opinion Leader event coming up on March 7, and details on how to tune in will be posted on the website before long. From our perspective — and we think this matters — these sessions aren't simply built as commercials for PL9643. What we really want is for the first portion to feature Dr. <<inaudible>>, who will discuss how he actually views and treats patients with dry eye disease and which current options he relies on. We're also going to walk through the several new approvals that have arrived in this space. We'll go over those, how they're affecting treatment, and what else is coming down the pike beyond PL9643 — there are other programs in development too. So we'll be touching on some of those as well. And of course, Dr. Michael Raizman, our Chief Medical Officer, who is also a highly respected ophthalmologist, will join us to go over the profile of 9643 — how it fits into potential disease treatment — along with the Phase 3 trial. So it's genuinely something you'll want to listen to; if you want to learn about dry eye disease, you'll learn a lot.
Michael Higgins
analystThat's quite useful, and I appreciate it. Thanks for keeping it to 9643. So, thinking ahead to the data, as you mentioned, in the second half of this year — how might that data affect how you're thinking about partnering it? What's your view on that going in? Thanks.
Carl Spana
executiveAll right, let me be clear on this — we have, obviously, a robust business development push underway. On a routine basis, we are in conversations with a range of possible partners regarding every one of our programs. Looking at the data, plainly, if that data turns out strongly positive, my expectation is that interest would be enormous. And then some choices will need to be made, depending on what opportunities present themselves — whether partnering at this point is what we want, or whether we prefer to keep moving ahead. Steve, I would never say to you that we won't pursue business development efforts around our various programs. What we aim for is maximizing value, and if that proves to be the right strategy, based on the data we're going to.
Michael Higgins
analystGot it. Moving on to 8177 — though part of that was inaudible. What's your view on partnering there? And regarding the trial design, will 8177 also include an interim analysis? Thanks.
Carl Spana
executiveYes, so on that point about 8177, the oral formulation that's designed—as we've mentioned several times—for two things. First, we believe it has great potential as a treatment for UC patients. But our goal really is to license that program. We don't see ourselves moving forward past this study in any form of inflammatory bowel disease, whether that's UC or anything else. This really is designed—actually, there was input from various potential partners. So it's been very helpful, as I don't think there's a GI franchise out there that hasn't taken a meeting around oral PL8177. We've received a tremendous amount of feedback on what we would need to demonstrate in the trial. And those things have been built in. According to the interim—there is an interim analysis, there is an interim just the last part, there is an interim analysis built into that study—that's what we will have, or that is the first 16 patients we will take a look at, and that's what the data will show by the end of the year.
Michael Higgins
analystGreat, thank you. Next, a few finance questions for Steve. At year end, what number of in-the-money warrants did you hold? Also, regarding the milestone from Palatin, which one did they earn? And I suppose a third part, perhaps tied to the back half of that milestone question, would be whether any others are expected this year. Thanks.
Steve Wills
executiveAppreciate that, Michael. Let me handle the simple piece first — warrants that are in the money at year-end: zero. Why is that? Since we have zero warrants outstanding, and that's a positive — a very clean cap table. $232 million in common shares outstanding, and 10%, 15% of that. On top of that we also include the options and equity grants for employees, bringing the total to roughly $266 million fully diluted. But once more, there are no warrants outstanding. So clearly, on the money question. As for the focus on the 250,000, I wouldn't really describe that as a milestone — that was contract revenue paid for the trial, for the clinical trial material, so they could move the program forward from a regulatory standpoint. Therefore the next milestones for either one — for each, whether it's planned on or focus on — will be regulatory ones. So we won't receive any milestones as they move ahead with any kind of clinical activity toward the regulatory filing. It will hinge on the regulatory filing and the approval. So we don't expect — don't anticipate anything further in '22 coming from them. That would be a 2023 event.
Michael Higgins
analystGreat. I appreciate the detail. Thanks, everyone. Congratulations once more.
Steve Wills
executiveThanks, Mike.
Carl Spana
executiveThanks, Mike.
Operator
operatorOur next question comes from John Newman at Canaccord. Go ahead, please.
John Newman
analystHey guys, thanks for taking the question. I was just wondering about the PL8177 study. It sounds like we'll see some interim analysis there later this year. I'm just curious, what are the endpoints that you'll be looking at at this stage of development there?
Carl Spana
executiveOur main goal is finding evidence of mucosal healing through colonoscopy. So the Mayo score is what we're using — the Mayo biopsy score serves as the primary measure we'll be evaluating. Naturally, we also have secondary endpoints that examine symptom relief. But bear in mind these patients receive treatment for eight weeks. As a result, we should anticipate fairly strong evidence of mucosal healing, and that typically leads, eventually leads, to relief of patient symptoms. There's likewise an entire range of secondary endpoints. This is a — a large amount of data is being gathered here, which is fairly standard for a proof-of-concept study.
John Newman
analystOkay, and one more thing about the PL9643 Melody study. When you look at the interim, will there be a chance, if you want, to lengthen either the treatment period or the follow-up for that trial? Or is the main focus just on how many patients you might potentially add there? Thanks.
Carl Spana
executiveSo that's simply a count of patients being added. The usual duration for these trials is a 12 week treatment period. We aren't going beyond that in this particular study; we might decide to do so for the second study, Melody 2, and we will definitely have those data in Melody 3, the open label safety extension, where we'll be gathering data across a full year of treatment. But it's a fairly simple question, really just about the power calculations. And given the standard deviations being observed, do they match? If they do, then we'll stay as we are, and if they believe the numbers should be raised somewhat, they'll advise us on how to raise them.
John Newman
analystThanks a lot, that's great.
Operator
operatorThat brings the question-and-answer portion of today's call to an end, ladies and gentlemen. Right now, I'd like to hand the conference back over to Dr. Spana so he can offer any additional or closing remarks.
Carl Spana
executiveI want to thank each of you for joining the Paladin Technologies second quarter fiscal 2022 conference call. There are good things taking place here. Plenty is going on. Every one of our programs is advancing and coming along well. So my thanks to all of you for taking part. We certainly also want to express appreciation to all our employees, collaborators, and patients for their involvement too. And Steve and I are eager to keep bringing you updates on how we are doing as the year goes on. Thank you, and have a wonderful day.
Operator
operatorLadies and gentlemen, that brings us to the end of today's conference. Thank you for joining us. You can disconnect at this time.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Palatin Technologies, Inc. transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Palatin Technologies, Inc. earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Palatin Technologies, Inc. or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.